Danaher Corporation
Danaher Corporation (DHR)
Overview
Danaher Corporation is a global science and technology company focused on the life sciences, diagnostics, and biotechnology markets. Headquartered in Washington, D.C., and listed on the New York Stock Exchange under the ticker DHR, Danaher traces its roots to 1984, when brothers Steven and Mitchell Rales founded the company (named after Danaher Creek in Montana). Once a diversified industrial conglomerate, Danaher has transformed itself over the past decade into a pure-play healthcare and life-sciences company through a series of spinoffs and acquisitions. The company generates roughly $23-25 billion in annual revenue, employs about 60,000 people worldwide, and carries a market capitalization in the neighborhood of $150 billion, placing it among the largest healthcare-adjacent names in the S&P 500.
What They Do & How They Make Money
Danaher does not sell a single product; it operates a portfolio of specialized science and technology businesses ("operating companies") that supply the instruments, consumables, software, and services used by researchers, biotech manufacturers, and clinical laboratories. Its money is made through a mix of high-margin capital equipment sales (instruments such as mass spectrometers, flow cytometers, and diagnostic analyzers) and, more importantly, recurring revenue from consumables, reagents, service contracts, and software that customers must repurchase continuously to keep those instruments running. This "razor and razor-blade" model — selling an installed base of equipment and then annuity-like consumables and service revenue on top — gives Danaher a large base of recurring, relatively predictable revenue and high customer switching costs. Danaher also grows through an active M&A program guided by its proprietary "Danaher Business System" (DBS), a continuous-improvement management methodology adapted from Toyota's lean manufacturing principles, which it uses to integrate acquisitions and improve margins across its operating companies.
Business Segments
As of its most recent reporting structure, Danaher organizes its business into three segments:
- Biotechnology (~28% of revenue): Provides technologies, consumables, and services used by biopharmaceutical companies to discover, develop, and manufacture biologic drugs, vaccines, cell and gene therapies, and other advanced therapeutics. Key businesses include Cytiva (bioprocessing equipment and consumables), Pall Corporation (filtration and purification), and Aldevron (mRNA, plasmid DNA, and protein production for gene-editing and vaccine developers).
- Life Sciences (~31% of revenue): Supplies the instruments, reagents, and software used in basic and translational research — mass spectrometry, flow cytometry, genomics, and microscopy. Core brands include Beckman Coulter Life Sciences, SCIEX, Leica Microsystems, Integrated DNA Technologies (IDT), and Abcam (acquired in 2023 for roughly $5.7 billion), which supplies research antibodies and reagents.
- Diagnostics (~41% of revenue and the largest segment): Makes clinical diagnostic instruments, test cartridges, and software used by hospitals, reference labs, and physician offices to diagnose disease and guide treatment. Key operating companies include Beckman Coulter Diagnostics (clinical chemistry and hematology), Cepheid (molecular/PCR point-of-care testing, notably for tuberculosis, HIV, and COVID-19), Leica Biosystems (cancer diagnostics), and Radiometer (blood gas and critical-care testing).
Danaher has substantially reshaped this portfolio in recent years, spinning off its industrial businesses as Fortive (2016) and its water-quality and product-identification businesses as Veralto (2023) to sharpen its focus on healthcare. In 2025 the company also entered into a roughly $10 billion agreement to acquire Masimo's consumer/non-healthcare-adjacent patient-monitoring business, a deal expected to further build out its diagnostics and monitoring capabilities.
Competitors
Danaher competes across each of its segments against other large, diversified life-science and diagnostics companies rather than a single rival:
- Life Sciences / research tools: Thermo Fisher Scientific, Agilent Technologies, Bio-Rad Laboratories, Bruker, Waters Corporation, and Sartorius.
- Biotechnology / bioprocessing: Thermo Fisher Scientific (Cytiva's closest direct rival), Sartorius Stedim Biotech, Merck KGaA (MilliporeSigma), and Repligen.
- Diagnostics: Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Becton Dickinson, and Bio-Mérieux, with Cepheid facing competition (and public scrutiny over pricing) in molecular point-of-care testing for infectious disease.
Competitive Position
Danaher's core competitive advantage is scale combined with process discipline: the Danaher Business System gives the company a repeatable playbook for acquiring science-and-technology businesses, cutting waste, and expanding margins, which has historically let Danaher pay premium prices for acquisitions and still generate strong returns. Its large, diversified installed base of instruments across biopharma, academic, and clinical-lab customers produces a substantial recurring-revenue annuity in consumables and service, which cushions the business from cyclicality in any one end market and gives it high switching costs and pricing power. Being one of only a handful of players (alongside Thermo Fisher and a few others) with true end-to-end capability — from early-stage research tools through biomanufacturing consumables to clinical diagnostics — also lets Danaher sell more deeply into large biopharma and hospital-system customers than narrower competitors can.
Key risks include a slower-than-expected recovery in bioprocessing and life-sciences instrument demand following the post-pandemic destocking cycle, as biotech funding and capital spending have been more subdued; exposure to China, a large and important but politically and economically volatile end market for its instruments; integration risk on large, recent acquisitions such as Abcam and the pending Masimo transaction; and reputational and regulatory pressure — most visibly around Cepheid's diagnostic cartridge pricing — from public-health advocacy groups pushing for lower-cost access to tests for tuberculosis, HIV, and other infectious diseases in lower-income countries.